Good News for HR+, HER2- Pre/Perimenopausal Pts!

Bestbird

If you are pre- or perimenopausal and have hormone receptor positive, HER2- MBC for which you have not yet had endocrine therapy, you'll want to read this!


At ASCO 2019, it was disclosed that adding Kisqali (Ribociclib) to hormonal therapy for pre- and perimenopausal hormone receptor positive, HER2 negative patients significantly increased Overall Survival (OS). These findings are based upon the MONALEESA-7 study, which enrolled 672 pre- and peri-menopausal patients who had not received prior hormonal therapy. The patients were randomized to receive either Kisqali or a placebo in combination with Tamoxifen (or Letrozole or Aromasin) and Zoladex, an ovarian suppression drug.


The study determined that the Kisqali combination resulted in 70.2% Overall Survival (OS) at 42 months vs. 46% OS in patients receiving hormone therapy without Kisqali. This corresponds to a 29% lower risk of death in patients receiving the Kisqali combination therapy.


Kisqali in combination with endocrine therapy has been approved in the US, Canada, Europe, and Australia (and potentially other countries) for pre- or perimenopausal patients who have hormone receptor positive, HER2- MBC. From: https://www.eurekalert.org/pub_releases/2019-06/uotm-rph053019.php


This and other information about approved treatments and cutting edge research can be found in my book, "The Insider's Guide to Metastatic Breast Cancer," which is also available in a complimentary .pdf. For more information, please visit: https://www.insidersguidembc.com/about

Hjertemor

This is GREAT news 🙏🏻

sugarcactus

I am thinking of enrolling in this study. I am 41 and am about to start a hormone treatment next week. I wonder if the side effects are tolerable. The study seems a little scary since low neutrophils can be a thing--I don't want to get sick as I'm around little kids all day!

Cure-ious

Sugarcactus- the low neutrophils on CDK4,6 inhibitors do not seem to pre-dispose us to infections in the way that low neutrophils during chemo does. This is because the cells are arrested in their maturation, rather than killed off- it takes quite awhile to develop mature and grow neutrophils, so chemo patients are profoundly depleted, but for us as soon as we go off the drugs, the cells start growing and resume their development from where they left off. They have not been able to demonstrate increased infections due to these drugs, which is a great thing. Also altho this trial was done with Kisquali, no significant differences have been found with Ibrance (or Versenio, for that matter) and so its likely they all work just as well, tho Versenio is stronger , does not affect neutrophil levels are much, and is dosed continuously. Good luck on your first treatment!!